|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Nabhan F, Dedhia PH and Ringel MD: Thyroid
cancer, recent advances in diagnosis and therapy. Int J Cancer.
149:984–992. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japan Associations of Endocrine Surgery
Task Force on the Guidelines for Thyroid Tumors (2024), . Clinical
practice guidelines on the management of thyroid tumors 2024. Japan
Assoc Endocr Surg. 41 (Suppl 2):S23–S42. 2024.
|
|
5
|
Hänscheid H, Lassmann M, Luster M, Thomas
SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M,
Ricard M, et al: Iodine biokinetics and dosimetry in radioiodine
therapy of thyroid cancer: Procedures and results of a prospective
international controlled study of ablation after rhTSH or hormone
withdrawal. J Nucl Med. 47:648–654. 2006.PubMed/NCBI
|
|
6
|
Stanojevic M, Savin S, Cvejic D, Djukic A,
Jeremic M and Zivancević Simonovic S: Comparison of the influence
of thyroglobulin antibodies on serum thyroglobulin values from two
different immunoassays in post surgical differentiated thyroid
carcinoma patients. J Clin Lab Anal. 23:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spencer CA, Takeuchi M, Kazarosyan M, Wang
CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS and Nicoloff JT:
Serum thyroglobulin autoantibodies: Prevalence, influence on serum
thyroglobulin measurement, and prognostic significance in patients
with differentiated thyroid carcinoma. J Clin Endocrinol Metab.
83:1121–1127. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrovic I, LoPresti J, Fatemi S,
Gianoukakis A, Burman K, Gomez-Lima CJ, Nguyen CT and Spencer CA:
Influence of thyroglobulin autoantibodies on thyroglobulin levels
measured by different methodologies: IMA, LC-MS/MS, and RIA. J Clin
Endocrinol Metab. 109:3254–3263. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cararo Lopes E, Sawant A, Moore D, Ke H,
Shi F, Laddha S, Chen Y, Sharma A, Naumann J, Guo JY, et al:
Integrated metabolic and genetic analysis reveals distinct features
of human differentiated thyroid cancer. Clin Transl Med.
13:e12982023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deja S, Dawiskiba T, Balcerzak W,
Orczyk-Pawiłowicz M, Głód M, Pawełka D and Młynarz P: Follicular
adenomas exhibit a unique metabolic profile. ¹H NMR studies of
thyroid lesions. PLoS One. 8:e846372013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abraham T and Schöder H: Thyroid
cancer-indications and opportunities for positron emission
tomography/computed tomography imaging. Semin Nucl Med. 41:121–138.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo L, Zhang Y, Li H, Li S and Guo X:
Clinical analysis of influencing factors on therapeutic effect of
radioactive iodine therapy in thyroglobulin antibodies positive
patients with papillary thyroid cancer. J Nucl Med. 63 (Suppl
2):S30062022.
|
|
13
|
Clish CB: Metabolomics: An emerging but
powerful tool for precision medicine. Cold Spring Harb Mol Case
Stud. 1:a0005882015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu S, Liu C, Hou Y, Li J, Guo Z, Chen X,
Zhang L, Peng S, Hong S, Xu L, et al: Integrative metabolomic
characterization identifies plasma metabolomic signature in the
diagnosis of papillary thyroid cancer. Oncogene. 41:2422–2430.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang N, Zhang Z, Chen X, Zhang G, Wang Y,
Pan L, Yan C, Yang G, Zhao L, Han J and Xue T: Plasma lipidomics
profiling reveals biomarkers for papillary thyroid cancer
diagnosis. Front Cell Dev Biol. 9:6822692021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Hu S, Miccoli P, Zeng Q, Liu S, Ran
L and Hu C: Non-invasive diagnosis of papillary thyroid
microcarcinoma: A NMR-based metabolomics approach. Oncotarget.
7:81768–81777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Razavi SA, Mahmanzar M, Nobakht M Gh BF,
Zamani Z, Nasiri S and Hedayati M: Plasma metabolites analysis of
patients with papillary thyroid cancer: A preliminary untargeted
1H NMR-based metabolomics. J Pharm Biomed Anal.
241:1159462024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monzen S, Tatara Y, Mariya Y, Chiba M,
Wojcik A and Lundholm L: HER2-positive breast cancer that resists
therapeutic drugs and ionizing radiation releases
sphingomyelin-based molecules to circulating blood serum. Mol Clin
Oncol. 13:702020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maxon HR, Thomas SR, Hertzberg VS,
Kereiakes JG, Chen IW, Sperling MI and Saenger EL: Relation between
effective radiation dose and outcome of radioiodine therapy for
thyroid cancer. N Engl J Med. 309:937–941. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schlesinger T, Flower MA and McCready VR:
Radiation dose assessments in radioiodine (131I) therapy. 1. The
necessity for in vivo quantitation and dosimetry in the treatment
of carcinoma of the thyroid. Radiother Oncol. 14:35–41. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Franken NAP, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Untergasser A, Cutcutache I, Koressaar T,
Ye J, Faircloth BC, Remm M and Rozen SG: Primer3-new capabilities
and interfaces. Nucleic Acids Res. 40:e1152012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanai Y: Amino acid transporter LAT1
(SLC7A5) as a molecular target for cancer diagnosis and
therapeutics. Pharmacol Ther. 230:1079642022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wittig A, Sauerwein WA and Coderre JA:
Mechanisms of transport of p-borono-phenylalanine through the cell
membrane in vitro. Radiat Res. 153:173–180. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wongthai P, Hagiwara K, Miyoshi Y,
Wiriyasermkul P, Wei L, Ohgaki R, Kato I, Hamase K, Nagamori S and
Kanai Y: Boronophenylalanine, a boron delivery agent for boron
neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.
Cancer Sci. 106:279–286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan R, Zhao X, Lei J and Zhou Q: Structure
of the human LAT1-4F2hc heteromeric amino acid transporter complex.
Nature. 568:127–130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bo T, Kobayashi S, Inanami O, Fujii J,
Nakajima O, Ito T and Yasui H: LAT1 inhibitor JPH203 sensitizes
cancer cells to radiation by enhancing radiation-induced cellular
senescence. Transl Oncol. 14:1012122021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Namikawa M, Kakizaki S, Kaira K, Tojima H,
Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y,
et al: Expression of amino acid transporters (LAT1, ASCT2 and xCT)
as clinical significance in hepatocellular carcinoma. Hepatol Res.
45:1014–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ericksen RE, Lim SL, McDonnell E, Shuen
WH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK, et al:
Loss of BCAA catabolism during carcinogenesis enhances mTORC1
activity and promotes tumor development and progression. Cell
Metab. 29:1151–1165.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanai Y, Segawa H, Miyamoto K, Uchino H,
Takeda E and Endou H: Expression cloning and characterization of a
transporter for large neutral amino acids activated by the heavy
chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fotiadis D, Kanai Y and Palacín M: The
SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med.
34:139–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Napolitano L, Scalise M, Galluccio M,
Pochini L, Albanese LM and Indiveri C: LAT1 is the transport
competent unit of the LAT1/CD98 heterodimeric amino acid
transporter. Int J Biochem Cell Biol. 67:25–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Häfliger P and Charles RP: The L-type
amino acid transporter LAT1-an emerging target in cancer. Int J Mol
Sci. 20:24282019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Xu Y, Li D, Fu L, Zhang X, Bao Y
and Zheng L: Review of the correlation of LAT1 with diseases:
mechanism and treatment. Front Chem. 8:5648092020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoshida F, Matsumura A, Shibata Y,
Yamamoto T, Nakauchi H, Okumura M and Nose T: Cell cycle dependence
of boron uptake from two boron compounds used for clinical neutron
capture therapy. Cancer Lett. 187:135–141. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsuya Y, Sato T, Kusumoto T, Yachi Y,
Seino R, Miwa M, Ishikawa M, Matsuyama S and Fukunaga H: Cell-cycle
dependence on the biological effects of boron neutron capture
therapy and its modification by polyvinyl alcohol. Sci Rep.
14:166962024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shah SH, Crosslin DR, Haynes CS, Nelson S,
Turer CB, Stevens RD, Muehlbauer MJ, Wenner BR, Bain JR, Laferrère
B, et al: Branched-chain amino acid levels are associated with
improvement in insulin resistance with weight loss. Diabetologia.
55:321–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McGarrah RW and White PJ: Branched-chain
amino acids in cardiovascular disease. Nat Rev Cardiol. 20:77–89.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wittig A, Sheu-Grabellus SY, Collette L,
Moss R, Brualla L and Sauerwein W: BPA uptake does not correlate
with LAT1 and Ki67 expressions in tumor samples (results of EORTC
trial 11001). Appl Radiat Isot. 69:1807–1812. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao H, Zhuang Y, Li R, Liu Y, Mei Z, He
Z, Zhou F and Zhou Y: Effects of different doses of X-ray
irradiation on cell apoptosis, cell cycle, DNA damage repair and
glycolysis in HeLa cells. Oncol Lett. 17:42–54. 2019.PubMed/NCBI
|
|
43
|
Keam S, MacKinnon KM, D'Alonzo RA, Gill S,
Ebert MA, Nowak AK and Cook AM: Effects of photon radiation on DNA
damage, cell proliferation, cell survival, and apoptosis of murine
and human mesothelioma cell lines. Adv Radiat Oncol. 7:1010132022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
ICRP, . Radiation dose to patients from
radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP
Publication 106. Approved by the Commission in October 2007. Ann
ICRP. 38:1–197. 2008.PubMed/NCBI
|
|
45
|
Du J, Ren W, Liu W, Zhou Y, Li Y, Lai Q,
Liu X, Chen T, Liu W, Chen Z, et al: Experimental study of
iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in
the treatment of hepatocellular carcinoma with internal
irradiation. BMC Cancer. 25:2452025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yan R, Li Y, Müller J, Zhang Y, Singer S,
Xia L, Zhong X, Gertsch J, Altmann KH and Zhou Q: Mechanism of
substrate transport and inhibition of the human LAT1-4F2hc amino
acid transporter. Cell Discov. 7:162021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Le Bricon T, Cynober L, Field CJ and
Baracos VE: Supplemental nutrition with ornithine
alpha-ketoglutarate in rats with cancer-associated cachexia:
Surgical treatment of the tumor improves efficacy of nutritional
support. J Nutr. 125:2999–3010. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Häfliger P, Graff J, Rubin M, Stooss A,
Dettmer MS, Altmann KH, Gertsch J and Charles RP: The LAT1
inhibitor JPH203 reduces growth of thyroid carcinoma in a fully
immunocompetent mouse model. J Exp Clin Cancer Res. 37:2342018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Enomoto K, Sato F, Tamagawa S, Gunduz M,
Onoda N, Uchino S, Muragaki Y and Hotomi M: A novel therapeutic
approach for anaplastic thyroid cancer through inhibition of LAT1.
Sci Rep. 9:146162019. View Article : Google Scholar : PubMed/NCBI
|
